Northern Trust
ENGN icon

Northern Trust’s enGene Therapeutics ENGN Stock Holding History

Northern Trust’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,085
Closed -$205K – 4477
2026
Q1 		$205K Hold
30,085
– – ﹤0.01% 3946
2025
Q4 		$272K Sell
30,085
-210
-0.7% -$1.68K ﹤0.01% 3870
2025
Q3 		$207K Sell
30,295
-2,731
-8% -$12.5K ﹤0.01% 3970
2025
Q2 		$120K Sell
33,026
-816
-2% -$3.06K ﹤0.01% 4072
2025
Q1 		$152K Sell
33,842
-574
-2% -$3.56K ﹤0.01% 4016
2024
Q4 		$229K Hold
34,416
– – ﹤0.01% 3944
2024
Q3 		$227K Buy
+34,416
New +$256K ﹤0.01% 3842

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Northern Trust's ENGN Position: Q2 2026 in Review

Northern Trust sold out of enGene Therapeutics (ENGN) in Q2 2026, closing a stake of 30,085 shares — an estimated $205K sold.

Northern Trust first reported a position in ENGN in Q3 2024 and held it in 7 quarters. The position peaked at $272K in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Northern Trust reported no remaining enGene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Northern Trust sold 30,085 enGene Therapeutics shares in Q2 2026, an estimated $205K.
  • Northern Trust first reported a position in enGene Therapeutics in Q3 2024 and held it in 7 quarters.
  • Northern Trust's enGene Therapeutics position peaked at $272K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.